BCL2 Jurkat
CRL-2899™
BCL2 Jurkat is a T lymphocyte cell line that was isolated in 2003 from the peripheral blood of a 14-year-old, male patient with leukemia, acute T cell. It was derived by transfecting the human Jurkat T cells with the pSFFV-neo mammalian expression vector containing the human BCL-2 ORF insert and a neomycin-resistant gene. This cell line was deposited by Stanley Korsmeyer and can be used in immunology and immune system disorder research.
Product category
Human cells
Organism
Homo sapiens, human
Cell type
T lymphocyte
Morphology
lymphoid-like
Tissue
Peripheral blood
Disease
Leukemia; Acute T Cell
Applications
3D cell culture
Immune system disorder research
Immunology
Product format
Frozen
Storage conditions
Vapor phase of liquid nitrogen
General
Specific applications
This cell line over-expresses BCL-2, and is useful to study cell apoptosis, BCL-2 function and its pathway.
Characteristics
Growth properties
Suspension
Derivation
The BCL2 Jurkat cell line was derived by transfecting human Jurkat T cells with the pSFFV-neo mammalian expression vector containing the human BCL-2 ORF insert and a neomycin-resistant gene (Addgene # 3349). Stable neomycin (Neo)-resistant single-cell-originated clones were isolated and expanded by selection in medium containing 1 mg/mL G418 for 14 days (1).
Age
14 years
Gender
Male
Tumorigenic
Yes
Genes expressed
Neomycin resistance gene; BCL2 over-expressed, verified at ATCC
Comments
The BCL2 Jurkat cell line was derived by transfecting human Jurkat T cells with the pSFFV-neo mammalian expression vector containing the human BCL-2 ORF insert and a neomycin-resistant gene (Addgene # 3349).
Stable neomycin (Neo)-resistant single-cell-originated clones were isolated and expanded by selection in medium containing 1 mg/mL G418 for 14 days (1). The BCL2 Jurkat cell line produces over-expression of human BCL-2.
Handling information
Quality control specifications
History
Legal disclaimers
